First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistant bacteria in the intensive care unit*
- 1 February 2005
- journal article
- editorial
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 33 (2) , 283-289
- https://doi.org/10.1097/01.ccm.0000152230.53473.a1
Abstract
The objective of this study was to determine the relationship between fluoroquinolone (FQ) use and subsequent emergence of multiple drug-resistant bacteria (MRB) in the intensive care unit (ICU). The authors conducted a prospective observational cohort study and a case control study. The study was conducted in a 30-bed ICU. All immunocompetent patients hospitalized for >48 hrs who did not receive antibiotics before ICU admission were eligible during a 15-month period. Routine MRB screening was performed at ICU admission and weekly thereafter. This screening included tracheal aspirate and nasal, anal, and axilla swabs. Univariate and multivariate analyses were used to determine risk factors for MRB emergence in the ICU. In addition, a case control study was performed to determine whether FQ use is associated with subsequent emergence of MRB. Two hundred thirty-nine patients were included; 108 ICU-acquired MRB were isolated in 77 patients. FQ use and longer duration of antibiotic treatment were identified as independent risk factors for MRB occurrence (odds ratio [95% confidence interval [CI] = 3.3 [1.7–6.5], 1.1 [1.0–1.2]; p p FQ use and longer duration of antibiotic treatment are independently associated with MRB emergence. Reducing antimicrobial treatment duration and restricting FQ use could be suggested to control MRB spread in the ICU.Keywords
This publication has 33 references indexed in Scilit:
- Acquisition of Multidrug‐ResistantPseudomonas aeruginosain Patients in Intensive Care Units: Role of Antibiotics with Antipseudomonal ActivityClinical Infectious Diseases, 2004
- Relationship between Fluoroquinolone Use and Changes in Susceptibility to Fluoroquinolones of Selected Pathogens in 10 United States Teaching Hospitals, 1991-2000Clinical Infectious Diseases, 2003
- Fluoroquinolones and the Risk for Methicillin-resistantStaphylococcus aureusin Hospitalized Patients1Emerging Infectious Diseases, 2003
- Antibiotic Resistance Among Gram-Negative Bacilli in US Intensive Care UnitsJAMA, 2003
- Antibiotic Use and the Prevalence of Antibiotic Resistance in Bacteria from Healthy Volunteers in the Dutch CommunityInfection, 2003
- Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobialsJournal of Antimicrobial Chemotherapy, 2002
- Trends in Fluoroquinolone (Ciprofloxacin) Resistance inEnterobacteriaceaefrom Bacteremias, England and Wales, 1990–1999Emerging Infectious Diseases, 2002
- Pseudomonas aeruginosaVentilator‐Associated Pneumonia: Comparison of Episodes Due to Piperacillin‐Resistant versus Piperacillin‐Susceptible OrganismsClinical Infectious Diseases, 2002
- Risk Factors for Persistent Carriage of Methicillin‐ResistantStaphylococcus aureusClinical Infectious Diseases, 2000
- Methicillin-Resistant Staphylococcus Aureus and Antimicrobial Use in Belgian HospitalsInfection Control & Hospital Epidemiology, 1999